RECURSION PHARMACEUTICALS, INC.RXRXEarnings & Financial Report
Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.
RXRX Q4 FY2025 Key Financial Metrics
Revenue
$35.5M
Gross Profit
$21.3M
Operating Profit
$-108.3M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
-304.2%
YoY Growth
681.7%
EPS
$-0.17
RECURSION PHARMACEUTICALS, INC. Q4 FY2025 Financial Summary
RECURSION PHARMACEUTICALS, INC. reported revenue of $35.5M (up 681.7% YoY) for Q4 FY2025, with a net profit of $-108.1M (up 39.6% YoY) (-304.2% margin). Cost of goods sold was $14.3M, operating expenses totaled $129.6M.
Key Financial Metrics
| Total Revenue | $35.5M |
|---|---|
| Net Profit | $-108.1M |
| Gross Margin | 59.8% |
| Operating Margin | -304.8% |
| Report Period | Q4 FY2025 |
RECURSION PHARMACEUTICALS, INC. Annual Revenue by Year
RECURSION PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $74.7M).
RECURSION PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
RECURSION PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $35.5M | +681.7% | $-108.1M | -304.2% |
| Q3 FY2025 | $5.2M | -80.2% | $-162.3M | -3135.3% |
| Q2 FY2025 | $19.2M | +33.3% | $-171.9M | -894.2% |
| Q1 FY2025 | $14.7M | +6.9% | $-202.5M | -1373.3% |
| Q4 FY2024 | $4.5M | -58.3% | $-178.9M | -3935.5% |
| Q3 FY2024 | $26.1M | +147.6% | $-95.8M | -367.5% |
| Q2 FY2024 | $14.4M | +30.9% | $-97.5M | -676.6% |
| Q1 FY2024 | $13.8M | +13.7% | $-91.4M | -662.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.8M | $14.4M | $26.1M | $4.5M | $14.7M | $19.2M | $5.2M | $35.5M |
| YoY Growth | 13.7% | 30.9% | 147.6% | -58.3% | 6.9% | 33.3% | -80.2% | 681.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $557.8M | $775.9M | $726.5M | $1.45B | $1.31B | $1.30B | $1.40B | $1.47B |
| Liabilities | $156.7M | $191.4M | $201.9M | $413.8M | $371.3M | $383.2M | $352.6M | $343.3M |
| Equity | $401.2M | $584.4M | $524.6M | $1.03B | $933.9M | $919.1M | $1.05B | $1.13B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-102.3M | $-82.2M | $-59.2M | $-115.4M | $-132.0M | $-76.4M | $-117.4M | $-46.1M |